Reuters logo
BRIEF-SC Fundamental Value Fund LP says ‍​believes that liquidation of Aviragen Therapeutics is superior to Vaxart's proposed transaction
November 9, 2017 / 11:37 AM / a month ago

BRIEF-SC Fundamental Value Fund LP says ‍​believes that liquidation of Aviragen Therapeutics is superior to Vaxart's proposed transaction

Nov 9 (Reuters) - Aviragen Therapeutics Inc

* SC Fundamental Value Fund LP says ‍​believes that liquidation of Aviragen Therapeutics Inc is superior to Vaxart Inc’s proposed transaction - SEC Filing

* SC Fundamental Value Fund LP says intends to vote against Vaxart Inc’s proposed transaction

* SC Fundamental Value Fund LP reports 6.19 percent stake in Aviragen Therapeutics Inc as of November 7 Source text: [bit.ly/2AobDrh] Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below